Genzyme Wins Cholesterol Drug Deal
18221
Genzyme has agreed to pay at least $325 million to win the hotly contested rights to a potentially powerful cholesterol-lowering drug.
198263
Researchers at US-based Alnylam Pharmaceuticals Inc blocked the action of a gene involved in cholesterol metabolism by using RNA interference (RNAi).
688289
The Food and Drug Administration approved Clolar, Genzyme Corp.'s new drug for patients under 21 with acute lymphocytic leukemia. An advisory panel on Dec. 1 recommended the drug be approved. Clolar was developed by Ilex Oncology Inc., the Texas firm Cambridge-based Genzyme acquired last week in a $1 billion stock transaction. The FDA panel recommended that more studies be done ...
67167
Forbes Medi-Tech Inc. hit a milestone on Friday, winning European approval for the use of its cholesterol-lowering ingredient, Reducol, in milk-based drinks in the European Union.
138104
Human Genome Sciences could see more than $180 million from a new deal with drug maker GlaxoSmithKline. Glaxo has acquired exclusive rights to an experimental drug called Albugon, which Human Genome Sciences
189561
US regulators said Tuesday they approved a new cancer drug from Genzyme Corp. for treating a type of childhood leukemia. The Food and Drug Administration, in a statement on its
301333
NEW YORK  - Genzyme Corp. announced  Wednesday that its drug Clolar has been approved by the U.S.  Food and Drug Administration (FDA) for the treatment of  children with difficult or relapsed acute lymphoblastic  leukemia (ALL).
134636
By harnessing a natural gene-silencing mechanism, scientists say they have dramatically reduced the activity of a protein linked to high cholesterol.
494130
Genzyme Corp. announced Wednesday that its drug Clolar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with difficult or relapsed acute lymphoblastic leukemia (ALL).
622953
In a settlement that the New York State attorney general said would transform the drug industry, GlaxoSmithKline agreed today to release the results of all its drug clinical trials.
412704
NEW YORK (CBS.MW) -- The Food and Drug Administration has approved Genzyme Corp. and Bioenvision Inc.&#39;s treatment for the most common type of childhood leukemia, sending shares of both companies higher Wednesday.
394537
A breakthrough cancer drug made by a Long Island company won federal approval late Thursday in a major victory for cancer patients and the region&#39;s budding biotech industry.
490579
Biotechnology company Genzyme Corp. said one of its experimental treatments for pain associated with osteoarthritis of the knee works no better than traditional steroids. The therapy, hylastan, is one of several viscosupplements -- injectable substances that lubricate the joints -- that Genzyme is developing to succeed its existing product, Synvisc.
683607
AtheroGenics announces the path forward for its lead drug.
198678
Biogen Idec and Irish drugmaker Elan Corp. won government approval yesterday to sell a new multiple sclerosis drug, Tysabri. The drug, which some analysts predict will bring in $2 billion
714179
SAN FRANCISCO - Genzyme Corp. won clearance from US regulators to market Renvela, a medicine for patients on kidney dialysis.
540596
TUESDAY, Dec. 18 (HealthDay News) -- A new kind of drug designed to lower levels of "bad" low-density lipoprotein (LDL) cholesterol and reduce heart disease risk has proved safe and effective in a phase II clinical trial, researchers report.